A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity.
about
Regulation of glucose homeostasis by GLP-1Modulation of Hypercholesterolemia-Induced Oxidative/Nitrative Stress in the HeartCardioprotective Signature of Short-Term Caloric RestrictionHearts from mice fed a non-obesogenic high-fat diet exhibit changes in their oxidative state, calcium and mitochondria in parallel with increased susceptibility to reperfusion injuryCardiovascular magnetic resonance detects the progression of impaired myocardial perfusion reserve and increased left-ventricular mass in mice fed a high-fat diet.DPP4 deficiency preserved cardiac function in abdominal aortic banding ratsLeft ventricular mechanical dysfunction in diet-induced obese mice is exacerbated during inotropic stress: a cine DENSE cardiovascular magnetic resonance studyObesity reduces left ventricular strains, torsion, and synchrony in mouse models: a cine displacement encoding with stimulated echoes (DENSE) cardiovascular magnetic resonance study.Insulin resistance and subclinical abnormalities of global and regional left ventricular function in patients with aortic valve sclerosis.p27 protein protects metabolically stressed cardiomyocytes from apoptosis by promoting autophagy.G protein-coupled receptors and the regulation of autophagy.GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study.Liraglutide Exerts Antidiabetic Effect via PTP1B and PI3K/Akt2 Signaling Pathway in Skeletal Muscle of KKAy Mice.Cardiomyocyte-specific loss of diacylglycerol acyltransferase 1 (DGAT1) reproduces the abnormalities in lipids found in severe heart failure.Exendin-4 improves cardiac function in mice overexpressing monocyte chemoattractant protein-1 in cardiomyocytes.Estradiol improves cardiovascular function through up-regulation of SOD2 on vascular wall.Exendin-4 ameliorates oxidized-LDL-induced inhibition of macrophage migration in vitro via the NF-κB pathwayLiraglutide attenuates high glucose-induced abnormal cell migration, proliferation, and apoptosis of vascular smooth muscle cells by activating the GLP-1 receptor, and inhibiting ERK1/2 and PI3K/Akt signaling pathways.Targeting metabolic disturbance in the diabetic heart.Design and rationale for the randomised, double-blinded, placebo-controlled Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS) crossover studyLiraglutide, a glucagon-like peptide-1 analog, increased insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp examination in patients with uncontrolled type 2 diabetes mellitus.Updating experimental models of diabetic cardiomyopathyGlucagon-Like Peptide 1 Protects against Hyperglycemic-Induced Endothelial-to-Mesenchymal Transition and Improves Myocardial Dysfunction by Suppressing Poly(ADP-Ribose) Polymerase 1 Activity.Inhibition of DPP-4 reduces acute mortality after myocardial infarction with restoration of autophagic response in type 2 diabetic rats.GLP1 protects cardiomyocytes from palmitate-induced apoptosis via Akt/GSK3b/b-catenin pathway.Impact of obesity on 7,12-dimethylbenz[a]anthracene-induced altered ovarian connexin gap junction proteins in female miceBK channel β1-subunit deficiency exacerbates vascular fibrosis and remodelling but does not promote hypertension in high-fat fed obesity in mice.Of mice (dogs) and men: getting to the heart of obesity-associated cardiac dysfunction.Protection against cardiac hypertrophy by geniposide involves the GLP-1 receptor / AMPKα signalling pathwaySignificance of Kampo, Japanese traditional medicine, in the treatment of obesity: basic and clinical evidence.Sitagliptin inhibits endothelin-1 expression in the aortic endothelium of rats with streptozotocin-induced diabetes by suppressing the nuclear factor-κB/IκBα system through the activation of AMP-activated protein kinase.Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese ratsAsiatic Acid Protects against Cardiac Hypertrophy through Activating AMPKα Signalling Pathway.Effect of Exendin-4 on Autophagy Clearance in Beta Cell of Rats with Tacrolimus-induced Diabetes Mellitus.Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner.Taking diabetes to heart--deregulation of myocardial lipid metabolism in diabetic cardiomyopathy.Energy intake correlates with the levels of fatty acid synthase and insulin-like growth factor-1 in male and female C57BL/6 mice.Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.Direct cardiovascular effects of glucagon like peptide-1.Antiatherothrombotic effects of dipeptidyl peptidase inhibitors.
P2860
Q24563430-DF034DE3-DDE0-4383-BBC0-8DC454DBAC33Q26770809-0B3FC087-B999-42A9-8D9F-B13C1255A9C7Q27303840-8A4CD413-745E-4D92-B2AB-3A93958553B2Q28388331-302ECA31-F26B-4792-B4DD-2808BBA4A1ABQ28388994-26BA19AA-9394-48D7-A2AA-A09BA5AFE6D9Q28538591-72F106D7-434F-4499-A30B-1D2C0185D1D1Q30278803-581F86F5-6394-4675-AE59-D041E945C193Q30415371-9C56F7E5-4FF8-4670-AB2D-82B8F7815E32Q33575953-E69ECC28-1E48-4762-9FA7-39E96235F961Q33761239-2AA7DDA7-FC60-40E3-8012-6FB9EE7240E2Q33847091-4ACD157D-7480-4E02-BADA-97A55AA9C2FAQ33917887-4FCACA2A-ED04-4C23-98C5-1A54C01240C1Q34087944-630EAA64-D5DE-41B2-8952-59B93946EDE7Q34396881-BCD624B3-0A54-4046-9534-5AEC057AA298Q34603269-FA895344-FC84-411E-A476-18B474DC9CADQ34980933-5C1981A8-76BA-4194-A287-24A307ED7B62Q35066447-3770C621-056E-439A-A4A8-DAD3A040D1D7Q35082511-4A707C82-8910-4F89-87EC-4BD46E3249D9Q35084845-4BBAE643-A012-4C0B-8039-E7B7CB762964Q35174285-3806FB25-8E8F-4895-97B1-AC4B971F2B62Q35438220-7CD37524-4D8A-4BA3-9249-912EEE440E4FQ35564129-5EDDD3D2-1C5F-4857-AD0E-22AB72ECDA66Q35707164-6A9EAFD8-4AF9-4B90-A1C7-E0BC4AC5E65FQ35936441-12B7E420-7CD0-4CF2-8698-83702DD62DA8Q36209853-72915A26-AD1A-4D3C-B561-B4DBF26D4BD6Q36271288-4DCAD972-2D2D-4E1B-BB54-53291CEA4C6CQ36550814-A0B08EFC-8D43-457B-A5B5-6BD826273BE5Q36611385-B762EE72-8D1D-48EC-A40C-0677A3D90BFDQ36797390-BCEE271B-1103-4D7A-96E9-02410AF4E8BDQ36804810-3D9CE342-29EB-4FC1-9178-10B7246143F1Q36901072-E0F408D2-3C5C-444A-8C42-675D2C4AEFF2Q36946065-D498D4C1-5C4C-4516-A117-98EF5E4B02D6Q37012154-43361507-880A-47FD-A41A-BB6599172DE1Q37111103-445F78AC-C7DF-4FA9-8499-051FA0929A73Q37274296-007A2334-40FB-4427-9A97-8111DB357957Q37457580-F6002677-FB3A-4763-9DA2-B3CC25096BF9Q37732928-16B7703F-1804-4503-8518-1E127A3F49D9Q38106411-7162FFC5-A938-4435-918C-7EB7D2264A81Q38132470-001CEC4E-4CD1-4110-9212-953DF8D5E72CQ38195527-0B81D6D2-1341-4431-8CAC-A0E78023D234
P2860
A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
A glucagon-like peptide-1 anal ...... n of a mouse model of obesity.
@en
A glucagon-like peptide-1 anal ...... n of a mouse model of obesity.
@nl
type
label
A glucagon-like peptide-1 anal ...... n of a mouse model of obesity.
@en
A glucagon-like peptide-1 anal ...... n of a mouse model of obesity.
@nl
prefLabel
A glucagon-like peptide-1 anal ...... n of a mouse model of obesity.
@en
A glucagon-like peptide-1 anal ...... n of a mouse model of obesity.
@nl
P2093
P1433
P1476
A glucagon-like peptide-1 anal ...... n of a mouse model of obesity.
@en
P2093
Allen Volchuk
Eric Akihiko Shikatani
Filio Billia
Ilya Mukovozov
Irmgard Schuiki
Lisa Annette Robinson
Mansoor Husain
Mohammad Hossein Noyan-Ashraf
P356
10.1161/CIRCULATIONAHA.112.091215
P407
P577
2012-11-27T00:00:00Z